

# Expression Pathology

## **EXPRESSION PATHOLOGY COLLABORATES ON LIQUID TISSUE® PERSONALIZED MEDICINE ASSAYS IN LUNG CANCER TREATMENT**

ROCKVILLE, Maryland (February 13, 2012) – Expression Pathology Inc. a leader in personalized medicine tissue protein analysis, today announced a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the company's tests for matching the most appropriate targeted therapies with lung cancer patients. The research will study the company's patented Liquid Tissue®-SRM technology, which enables accurate measurement of proteins in tumor pathways.

Lung cancer is the leading cause of cancer-related deaths worldwide. In the United States alone, there were an estimated 226,160 new cases and 160,340 deaths in 2012, with lung cancer accounting for 15% of cancer diagnoses but 28% of cancer deaths (American Cancer Society, Cancer Facts & Figures 2012).

A new generation of lung cancer drugs that target specific tumor pathways is having a significant positive impact on treatment, but improved testing methods are needed to help guide drug selection. The advantage of Expression Pathology's Liquid Tissue® SRM technology is the unique ability to quantify - in a single assay - multiple proteins involved in tumor pathways, in formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of tissue preservation employed in medical practice worldwide.

### **About Expression Pathology**

Expression Pathology Inc. is a private biotechnology company focused on advancing personalized medicine with tumor tests that improve cancer treatment decisions while reducing health care costs. The company has translated its patented Liquid Tissue® SRM technology platform into a pipeline of innovative cancer pathway tests that have entered clinical studies with top tier cancer treatment centers and are being used by pharmaceutical companies in development of new cancer drugs.

The company's tests employ a mass spectrometry technique called Selected Reaction Monitoring (SRM) which can simultaneously and quantitatively measure many proteins at a time. Liquid Tissue® SRM methodology and tests are covered by four issued and 28 pending U.S. and international patents.

For more information, please visit [www.expressionpathology.com](http://www.expressionpathology.com).

For more information please contact:

Peter Tunon  
VP Sales and Marketing  
Expression Pathology Inc.  
9620 Medical Center Drive  
Rockville, MD 20850

301.977.3654  
Email [p.tunon@expressionpathology.com](mailto:p.tunon@expressionpathology.com)